The United States market has shown strong performance recently, with a 1.8% increase over the last week and a notable 30% rise over the past year, alongside forecasts of annual earnings growth of 16%. In such a robust market environment, identifying stocks with solid fundamentals is crucial for investors looking to capitalize on growth opportunities. While the term "penny stocks" may seem outdated, it still refers to smaller or newer companies that can offer significant value when they possess strong financials and clear growth potential.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$2.99	$190.39M	✅ 3 ⚠️ 2 View Analysis >
WM Technology (MAPS)	$0.348	$60.27M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.08	$355.04M	✅ 3 ⚠️ 2 View Analysis >
CI&T (CINT)	$3.88	$515.44M	✅ 5 ⚠️ 0 View Analysis >
Information Services Group (III)	$3.11	$196.42M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.82	$395.62M	✅ 3 ⚠️ 1 View Analysis >
Village Farms International (VFF)	$2.74	$319.99M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$331.71M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.905	$6.57M	✅ 2 ⚠️ 3 View Analysis >

Here we highlight a subset of our preferred stocks from the screener.

Vuzix (VUZI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Vuzix Corporation designs, manufactures, and markets AI-powered smart glasses, waveguides, and AR technologies globally with a market cap of $221.20 million.

Operations: The company generates revenue from its Video Eyewear Products segment, which amounted to $6.28 million.

Market Cap: $221.2M

Vuzix Corporation, with a market cap of US$221.20 million, has been making strides in the smart glasses sector despite financial challenges. Recent six-figure orders from AcuraFlow and aerospace clients highlight growing adoption of its technology in industrial and defense applications. While revenue increased to US$6.28 million last year, the company remains unprofitable with significant losses and less than a year of cash runway if current spending trends continue. Vuzix's experienced management team is navigating high volatility and leveraging strategic partnerships to expand its market presence amidst these financial constraints.

ZJK Industrial (ZJK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ZJK Industrial Co., Ltd. operates through its subsidiaries to manufacture and sell precision fasteners, structural parts, and other precision metal products across China, Taiwan, Singapore, the United States, and internationally with a market cap of approximately $190.39 million.

Operations: ZJK Industrial Co., Ltd. has not reported any specific revenue segments.

Market Cap: $190.39M

ZJK Industrial, with a market cap of approximately US$190.39 million, has demonstrated strong financial performance, reporting a revenue increase to US$56.1 million for 2025 from US$37.81 million the previous year and net income growth to US$10.19 million from US$3.68 million. The company is debt-free and maintains a robust balance sheet with short-term assets of $59.5M exceeding both short and long-term liabilities significantly. Despite its high volatility, ZJK's earnings have grown at an impressive rate of 176.6% over the past year, showcasing substantial profit margin improvements and a high return on equity at 23.3%.

Nuvation Bio (NUVB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that develops product candidates for cancer treatment, with a market cap of approximately $1.54 billion.

Operations: Nuvation Bio Inc. currently does not report any revenue segments.

Market Cap: $1.54B

Nuvation Bio, with a market cap of approximately US$1.54 billion, recently reported significant revenue growth to US$83.23 million in Q1 2026 from US$3.08 million a year ago, marking its transition from pre-revenue status. The company has achieved profitability with a net income of US$5.4 million compared to a net loss previously, driven by the success of taletrectinib (IBTROZI), which is now included in NCCN Guidelines for CNS cancers and approved in multiple countries for ROS1+ NSCLC treatment. Despite being unprofitable historically, Nuvation's strong cash position and minimal debt provide financial resilience as it continues clinical trials and product development initiatives globally.

Next Steps

• Reveal the 343 hidden gems among our US Penny Stocks screener with a single click here.
• Searching for a Fresh Perspective? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.